Hagino, T.; Hamada, R.; Yoshida, M.; Saeki, H.; Fujimoto, E.; Kanda, N.
Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study. Pharmaceuticals 2024, 17, 519.
https://doi.org/10.3390/ph17040519
AMA Style
Hagino T, Hamada R, Yoshida M, Saeki H, Fujimoto E, Kanda N.
Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study. Pharmaceuticals. 2024; 17(4):519.
https://doi.org/10.3390/ph17040519
Chicago/Turabian Style
Hagino, Teppei, Risa Hamada, Mai Yoshida, Hidehisa Saeki, Eita Fujimoto, and Naoko Kanda.
2024. "Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study" Pharmaceuticals 17, no. 4: 519.
https://doi.org/10.3390/ph17040519
APA Style
Hagino, T., Hamada, R., Yoshida, M., Saeki, H., Fujimoto, E., & Kanda, N.
(2024). Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study. Pharmaceuticals, 17(4), 519.
https://doi.org/10.3390/ph17040519